At the time of writing, Puma Biotechnology Inc [PBYI] stock is trading at $3.35, down -6.42%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PBYI shares have gain 15.92% over the last week, with a monthly amount glided 10.20%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Puma Biotechnology Inc [NASDAQ: PBYI] stock has seen the most recent analyst activity on September 28, 2021, when Citigroup upgraded its rating to a Buy but kept the price target unchanged to $11 for it. On October 08, 2019, downgrade downgraded it’s rating to Sell and revised its price target to $8 on the stock. Citigroup downgraded its rating to a Neutral but stick to its price target of $24 on May 10, 2019. Cantor Fitzgerald downgraded its rating to a Neutral and reduced its price target to $20 on May 10, 2019. Leerink Partners started tracking with a Mkt Perform rating for this stock on January 17, 2019, and assigned it a price target of $21. In a note dated January 03, 2019, Guggenheim downgraded an Neutral rating on this stock.
For the past year, the stock price of Puma Biotechnology Inc fluctuated between $2.22 and $7.15. Puma Biotechnology Inc [NASDAQ: PBYI] shares were valued at $3.35 at the most recent close of the market.
Analyzing the PBYI fundamentals
According to Puma Biotechnology Inc [NASDAQ:PBYI], the company’s sales were 230.47M for trailing twelve months, which represents an -18.15% plunge. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.1%, and Net Profit Margin reading is 0.1%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is 0.41 and Total Capital is 0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.24 points at the first support level, and at 3.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.55, and for the 2nd resistance point, it is at 3.76.
Ratios To Look Out For
It is important to note that Puma Biotechnology Inc [NASDAQ:PBYI] has a current ratio of 1.54. As well, the Quick Ratio is 1.45, while the Cash Ratio is 0.61. Considering the valuation of this stock, the price to sales ratio is 0.72, the price to book ratio is 1.79 and price to earnings (TTM) ratio is 5.49.
Transactions by insiders
Recent insider trading involved NOUGUES MAXIMO F, Chief Financial Officer, that happened on Jan 02 ’25 when 10227.0 shares were sold. Chief Commercial Officer, Ludwig Jeffrey Jerome completed a deal on Jan 02 ’25 to sell 9437.0 shares. Meanwhile, HUNT DOUGLAS M sold 8633.0 shares on Jan 02 ’25.
